18 July 2023 in British Journal of Dermatology
Background: Facial angiofibromas (FAs) are a major feature of tuberous sclerosis complex (TSC). Topical rapamycin can successfully treat FAs. A new stabilized cream formulation that protects rapamycin from oxidation has been developed in 0.5% and 1% concentrations. Objectives: To assess the efficacy and safety of a novel, stabilized topical rapamycin cream formulation. Methods: This multicentre double-blind randomized placebo-controlled dose–response phase II/III study with a parallel design included participants aged 6–65 years with FAs of mild or moderate severity according to the Investigator’s Global Assessment (IGA) scale. Participants were randomized to one of three treatment arms: topical rapamycin 0.5%, topical rapamycin 1% or placebo. Treatment was applied once daily for 26 weeks. Safety and efficacy measures were assessed at days 14, 56, 98, 140 and 182. The primary endpoint was the percentage of participants achieving IGA scores of ‘clear’ or ‘almost clear’ after 26 weeks of treatment. Secondary measures included Facial Angiofibroma Severity Index (FASI) and participant- and clinician-reported percentage-based improvement. Safety measures included the incidence of treatment-emergent adverse events and blood rapamycin concentration changes over time. Results: Participants (n = 107) were randomized to receive either rapamycin 1% (n = 33), rapamycin 0.5% (n = 36) or placebo (n = 38). All treated participants were included in the final analysis. The percentage of participants with a two-grade IGA improvement was greater in the rapamycin 0.5% treatment group (11%) and rapamycin 1% group (9%) than in the placebo group (5%). However, this was not statistically significant [rapamycin 0.5%: odds ratio (OR) 1.71, 95% confidence interval (CI) 0.36–8.18 (P = 0.50); rapamycin 1%: OR 1.68, 95% CI 0.33–8.40 (P = 0.53)]. There was a statistically significant difference in the proportion of participants treated with rapamycin cream that achieved at least a one-grade improvement in IGA [rapamycin 0.5%: 56% (OR 4.73, 95% CI 1.59–14.10; P = 0.005); rapamycin 1%: 61% (OR 5.14, 95% CI 1.70–15.57; P = 0.004); placebo: 24%]. Skin adverse reactions were more common in patients following rapamycin application (64%) vs. placebo (29%). Conclusions: Both rapamycin cream formulations (0.5% and 1%) were well tolerated, and either strength could lead to clinical benefit in the treatment of FA.
1 May 2022 in JCO Precision Oncology
SHH medulloblastoma from GNAS mutation (molecular profiling confirmation) with osteoma cutis & syndromic features.
29 March 2025 in Journal of Investigative Dermatology
10 April 2023 in Pediatric Transplantation
31 July 2023 in Dermatology Practical & Conceptual
Citation: Costello CM, Besch-Stokes JG, Shahin AB, Bottjer JR, Price HN, Swanson DL. The Use of Patient-Marketed Dermatoscopes in Dermatology Practice. Dermatol Pract Concept. 2023;13(3):e2023220. DOI: https://doi.org/10.5826/dpc.1303a220 Accepted: April 4, 2023; Published: July 2023 Copyright: ©2023 Costello et al. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (BY-NC-4.0), https://creativecommons.org/licenses/by-nc/4.0/, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original authors and source are credited. Funding: None. Competing interests: None. Authorship: All authors have contributed significantly to this publication. Corresponding author: David L Swanson, MD, Mayo Clinic – Department of Dermatology 13400 E Shea Blvd, Scottsdale, AZ 85259. Phone: 480-301-8508; Fax: 480-301-9272 Email: swanson.david@mayo.edu Keywords : Dermoscopy, Patient-focused dermoscopy, teledermatology, telemedicine This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.